- Home
- CANF vs ASTC Comparison
CANF vs ASTC Comparison
Compare CANF & ASTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- ASTC
- Stock Information
- Founded
- CANF 1994
- ASTC 1984
- Country
- CANF Israel
- ASTC United States
- Employees
- CANF N/A
- ASTC N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- ASTC Biotechnology: Laboratory Analytical Instruments
- Sector
- CANF Health Care
- ASTC Industrials
- Exchange
- CANF Nasdaq
- ASTC Nasdaq
- Market Cap
- CANF 14.4M
- ASTC 13.6M
- IPO Year
- CANF N/A
- ASTC 1995
- Fundamental
- Price
- CANF $2.00
- ASTC $8.10
- Analyst Decision
- CANF Strong Buy
- ASTC
- Analyst Count
- CANF 2
- ASTC 0
- Target Price
- CANF $14.00
- ASTC N/A
- AVG Volume (30 Days)
- CANF 111.6K
- ASTC 14.9K
- Earning Date
- CANF 11-15-2024
- ASTC 11-11-2024
- Dividend Yield
- CANF N/A
- ASTC N/A
- EPS Growth
- CANF N/A
- ASTC N/A
- EPS
- CANF N/A
- ASTC N/A
- Revenue
- CANF $667,000.00
- ASTC $1,664,000.00
- Revenue This Year
- CANF $356.93
- ASTC N/A
- Revenue Next Year
- CANF N/A
- ASTC N/A
- P/E Ratio
- CANF N/A
- ASTC N/A
- Revenue Growth
- CANF N/A
- ASTC 121.87
- 52 Week Low
- CANF $1.81
- ASTC $7.00
- 52 Week High
- CANF $4.69
- ASTC $12.29
- Technical
- Relative Strength Index (RSI)
- CANF 38.27
- ASTC 42.10
- Support Level
- CANF $1.87
- ASTC $7.83
- Resistance Level
- CANF $2.04
- ASTC $8.29
- Average True Range (ATR)
- CANF 0.14
- ASTC 0.32
- MACD
- CANF 0.01
- ASTC 0.05
- Stochastic Oscillator
- CANF 38.24
- ASTC 55.73
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About ASTC Astrotech Corporation (DE)
Astrotech Corp is a science and technology development company. The firm invents, acquires, and commercializes technological innovations sourced from internal research, universities, laboratories, and research institutions. The 1st Detect develops, manufactures, and sells chemical analyzers for use in the airport security, military, breath analysis markets. AgLAB develops a series of mass spectrometers for use in the agriculture market.